Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable MetastaticColorectalCancer: An Endorsement of a Canadian Consensus Statement Guideline Endorsement 2-31 Guideline Endorsement 2-31 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable MetastaticColorectalCancer: An Endorsement of a Canadian Consensus (...) Statement R. Goodwin, C. Agbassi, E. Kennedy, J. Biagi, R. Wong, S. Welch, S. Berry, and the Gastrointestinal Disease Site Group Report Date: July 3, 2018 This document describes the CCO- Gastrointestinal Cancer Disease Site Group endorsement of The predictive effect of primary tumour location in the treatment of metastaticcolorectalcancer: a Canadian consensus statement published in 2017 by Abrahao et al. The original publication is available at Current Oncology Vol 24, No 6 (2017) For information
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated MetastaticColorectalCancer: The FRESCO Randomized Clinical Trial. Importance: Patients with metastaticcolorectalcancer (CRC) have limited effective and tolerable treatment options. Objective: To evaluate the efficacy and safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients with metastatic CRC. Design, Setting (...) , and Participants: FRESCO (Fruquintinib Efficacy and Safety in 3+ Line ColorectalCancer Patients) was a randomized, double-blind, placebo-controlled, multicenter (28 hospitals in China), phase 3 clinical trial. From December 2014 to May 2016, screening took place among 519 patients aged 18 to 75 years who had metastatic CRC that progressed after at least 2 lines of chemotherapy but had not received VEGFR inhibitor therapy; 416 met the eligibility criteria and were stratified by prior anti-VEGF therapy and K
Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectalcancer liver metastases: a meta-analysis of randomised trials 30018809 2018 11 14 2059-7029 3 4 2018 ESMO open ESMO Open Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectalcancer liver metastases: a meta-analysis of randomised trials. e000343 10.1136/esmoopen-2018-000343 Surgical resection is the only option of cure for patients with metastaticcolorectalcancer (...) . Risk of recurrence after metastasectomy is around 75%. Use of adjuvant chemotherapy after metastasectomy is controversial. To address whether adjuvant systemic therapy after colorectalcancer metastasectomy offers any survival benefit compared with surgery alone. Systematic review of literature and meta-analysis of all available randomised evidence. Relative hazards (RHs) were summarised across trials and heterogeneity was assessed with the Q and I2 statistics. Five trials were eligible. Three
Role of chemotherapy in resectable liver metastases from colorectalcancer: food for thought from pooled evidence 29942665 2018 11 14 2059-7029 3 4 2018 ESMO open ESMO Open Role of chemotherapy in resectable liver metastases from colorectalcancer: food for thought from pooled evidence. e000367 10.1136/esmoopen-2018-000367 Mauri Davide D Department of Medical Oncology, University Medical School of Ioannina, Ioannina, Greece. Filis Panagiotis P Department of Medical Oncology, University Medical (...) School of Ioannina, Ioannina, Greece. Tsali Lampriani L Department of Internal Medicine, General Hospital of Arta, Arta, Greece. Zarkavelis George G Department of Medical Oncology, University Medical School of Ioannina, Ioannina, Greece. Pentheroudakis George G Department of Medical Oncology, University Medical School of Ioannina, Ioannina, Greece. eng Editorial 2018 06 19 England ESMO Open 101690685 2059-7029 colorectal liver metastasectomy chemotherapy Competing interests: None declared. 2018 04 30
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastaticcolorectalcancer 29942666 2018 11 14 2059-7029 3 4 2018 ESMO open ESMO Open Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastaticcolorectalcancer (...) . e000375 10.1136/esmoopen-2018-000375 5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastaticcolorectalcancer (mCRC). Checkpoint inhibitors targeting PD-1/PD-L1 demonstrated efficacy on mCRC with microsatellite instability but remain ineffective alone in microsatellite stable tumour. 5-Fluorouracil and oxaliplatin were known to present immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb
Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and ColorectalCancer 30084749 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and ColorectalCancer. 1-10 10.1200/JGO.18.00018 Purpose Epidemiologic data from several populations suggest that metformin may decrease cancer risk and mortality in patients (...) with colorectalcancer (CRC) and type II diabetes mellitus (DM). Although type II DM and CRC are major health problems in the Middle East, no investigations have been performed to test the effect metformin has on the outcome of patients with type II DM and CRC who are also treated with metformin. Materials and Methods We retrospectively reviewed the medical records of 1,902 patients diagnosed with CRC at King Hussein Cancer Center between January 2004 and December 2012, and identified 349 patients (18
Clonal evolution of colorectalcancer in a patient with serially resected metastases and liquid biopsies: a case report and discussion of the literature 29942663 2018 11 14 2059-7029 3 4 2018 ESMO open ESMO Open Clonal evolution of colorectalcancer in a patient with serially resected metastases and liquid biopsies: a case report and discussion of the literature. e000329 10.1136/esmoopen-2018-000329 Metastaticcolorectalcancer represents a striking example of clonal heterogeneity and tumour (...) evolution, which generates acquired resistance to therapy. Once hard to perform, the study of clonal heterogeneity is now significantly aided by the use of liquid biopsies. We herein report a case of a patient with colorectalcancer and serial development of multiple metastases which were all resected and genotyped. A rare point mutation was identified in the primary tumour (but not in any of the organ metastatic sites), as well as in the first and the last out of three consecutive liquid biopsies
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectalcancer (SCOT): an international, randomised, phase 3, non-inferiority trial 29611518 2018 04 08 1474-5488 19 4 2018 Apr The Lancet. Oncology Lancet Oncol. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectalcancer (SCOT): an international, randomised, phase 3, non-inferiority trial. 562-578 S1470-2045(18)30093-7 10.1016/S1470-2045(18)30093-7 6 months (...) of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectalcancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectalcancer underwent central randomisation with minimisation for centre, choice of regimen, sex
A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectalcancer prognosis 29872543 2018 12 21 2056-7189 4 2018 NPJ systems biology and applications NPJ Syst Biol Appl A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectalcancer prognosis. 20 10.1038/s41540-018-0056-1 Recent advances in high-throughput technologies have provided an unprecedented opportunity (...) applications. Here, we have evaluated the role of circulating microRNA as a means of predicting the prognosis of patients with colorectalcancer, which is the second leading cause of cancer-related death worldwide. We have developed a multi-objective optimisation method that effectively integrates a data-driven approach with the knowledge obtained from the microRNA-mediated regulatory network to identify robust plasma microRNA signatures which are reliable in terms of predictive power as well as functional
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastaticcolorectalcancer (AXEPT): a multicentre, open-label, randomised, non- 29555258 2018 05 04 1474-5488 19 5 2018 May The Lancet. Oncology Lancet Oncol. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line (...) therapy for metastaticcolorectalcancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. 660-671 S1470-2045(18)30140-2 10.1016/S1470-2045(18)30140-2 Studies of a modified XELIRI (mXELIRI; capecitabine plus irinotecan) regimen suggest promising efficacy and tolerability profiles in the first-line and second-line settings. Therefore, we aimed to compare the efficacy and safety of the mXELIRI regimen with that of standard FOLFIRI (leucovorin, fluorouracil, and irinotecan
Effect of More vs Less Frequent Follow-up Testing on Overall and ColorectalCancer-Specific Mortality in Patients With Stage II or III ColorectalCancer: The COLOFOL Randomized Clinical Trial. Importance: Intensive follow-up of patients after curative surgery for colorectalcancer is common in clinical practice, but evidence of a survival benefit is limited. Objective: To examine overall mortality, colorectalcancer-specific mortality, and colorectalcancer-specific recurrence rates among (...) patients with stage II or III colorectalcancer who were randomized after curative surgery to 2 alternative schedules for follow-up testing with computed tomography and carcinoembryonic antigen. Design, Setting, and Participants: Unblinded randomized trial including 2509 patients with stage II or III colorectalcancer treated at 24 centers in Sweden, Denmark, and Uruguay from January 2006 through December 2010 and followed up for 5 years; follow-up ended on December 31, 2015. Interventions: Patients
Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With ColorectalCancer. Importance: Surveillance testing is performed after primary treatment for colorectalcancer (CRC), but it is unclear if the intensity of testing decreases time to detection of recurrence or affects patient survival. Objective: To determine if intensity of posttreatment surveillance is associated with time to detection of CRC recurrence, rate of recurrence (...) , resection for recurrence, or overall survival. Design, Setting, and Participants: A retrospective cohort study of patient data abstracted from the medical record as part of a Commission on Cancer Special Study merged with records from the National Cancer Database. A random sample of patients (n=8529) diagnosed with stage I, II, or III CRC treated at a Commission on Cancer-accredited facilities (2006-2007) with follow-up through December 31, 2014. Exposures: Intensity of imaging and carcinoembryonic
Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectalcancer 29862052 2018 06 04 2059-7029 3 4 2018 ESMO open ESMO Open Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectalcancer. e000377 10.1136/esmoopen-2018-000377 Argiles Guillem G Gastrointestinal Malignancies Program, Vall d'Hebron University Hospital, Barcelona, Spain (...) . eng Journal Article 2018 05 20 England ESMO Open 101690685 2059-7029 colorectalcancer Competing interests: None declared. 2018 6 5 6 0 2018 6 5 6 0 2018 6 5 6 1 epublish 29862052 10.1136/esmoopen-2018-000377 esmoopen-2018-000377 PMC5976108
Interaction between Host MicroRNAs and the Gut Microbiota in ColorectalCancer 29795787 2018 11 14 2379-5077 3 3 2018 May-Jun mSystems mSystems Interaction between Host MicroRNAs and the Gut Microbiota in ColorectalCancer. e00205-17 10.1128/mSystems.00205-17 Although variation in gut microbiome composition has been linked with colorectalcancer (CRC), the factors that mediate the interactions between CRC tumors and the microbiome are poorly understood. MicroRNAs (miRNAs) are known to regulate (...) in the recruitment of pathogenic microbial taxa. Our work characterized a global relationship between microbial community composition and miRNA expression in human CRC tissues. IMPORTANCE Recent studies have found an association between colorectalcancer (CRC) and the gut microbiota. One potential mechanism by which the microbiota can influence host physiology is through affecting gene expression in host cells. MicroRNAs (miRNAs) are small noncoding RNA molecules that can regulate gene expression and have
Association of Colonoscopy Adenoma Findings With Long-term ColorectalCancer Incidence. Importance: Individuals with adenomatous polyps are advised to undergo repeated colonoscopy surveillance to prevent subsequent colorectalcancer (CRC), but the relationship between adenomas at colonoscopy and long-term CRC incidence is unclear. Objective: To compare long-term CRC incidence by colonoscopy adenoma findings. Design, Setting, and Participants: Multicenter, prospective cohort study (...) of participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer randomized clinical trial of flexible sigmoidoscopy (FSG) beginning in 1993 with follow-up for CRC incidence to 2013 across the United States. Participants included 154 900 men and women aged 55 to 74 years enrolled in PLCO of whom 15 935 underwent colonoscopy following their first positive FSG screening result. The final day of follow-up was December 31, 2013. Exposures: Enrolled participants had been randomized to FSG or usual care
Optimising the use of cetuximab in the continuum of care for patients with metastaticcolorectalcancer 29765773 2018 11 14 2059-7029 3 4 2018 ESMO open ESMO Open Optimising the use of cetuximab in the continuum of care for patients with metastaticcolorectalcancer. e000353 10.1136/esmoopen-2018-000353 The anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with chemotherapy is a standard of care in the first-line treatment of RAS wild-type (wt) metastatic (...) colorectalcancer (mCRC) and has demonstrated efficacy in later lines. Progressive disease (PD) occurs when tumours develop resistance to a therapy, although controversy remains about whether PD on a combination of chemotherapy and targeted agents implies resistance to both components. Here, we propose that some patients may gain additional clinical benefit from the reuse of cetuximab after having PD on regimens including cetuximab in an earlier treatment line. We conducted a non-systematic literature
Effect of public reporting of surgeons' outcomes on patient selection, "gaming," and mortality in colorectalcancer surgery in England: population based cohort study. OBJECTIVE: To determine the effect of surgeon specific outcome reporting in colorectalcancer surgery on risk averse clinical practice, "gaming" of clinical data, and 90 day postoperative mortality. DESIGN: National cohort study. SETTING: English National Health Service hospital trusts. POPULATION: 111 431 patients diagnosed (...) as having colorectalcancer from 1 April 2011 to 31 March 2015 included in the National Bowel Cancer Audit. INTERVENTION: Public reporting of surgeon specific 90 day mortality in elective colorectalcancer surgery in England introduced in June 2013. MAIN OUTCOME MEASURES: Proportion of patients with colorectalcancer who had an elective major resection, predicted 90 day mortality based on characteristics of patients and tumours, and observed 90 day mortality adjusted for differences in characteristics
ColorectalCancer Screening Revised 2018 ACR Appropriateness Criteria ® 1 ColorectalCancer Screening American College of Radiology ACR Appropriateness Criteria ® ColorectalCancer Screening Variant 1: Colorectalcancer screening. Average-risk individual. Age greater than or equal to 50 years. Initial screening, then follow-up every 5 years after initial negative screen. Procedure Appropriateness Category Relative Radiation Level CT colonography Usually Appropriate ??? X-ray barium enema double (...) -contrast May Be Appropriate ??? MR colonography May Be Appropriate O X-ray barium enema single-contrast Usually Not Appropriate ??? Variant 2: Colorectalcancer screening. Moderate-risk individual. First-degree family history of cancer or adenoma. Initial screening, then follow-up every 5 years after initial negative screen. Procedure Appropriateness Category Relative Radiation Level CT colonography Usually Appropriate ??? X-ray barium enema double-contrast May Be Appropriate ??? MR colonography May